Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Novo Nordisk has signed a partnership deal with Aspect Biosystems that could be worth as much as $2.6 billion, the latest example of a Big Pharma betting big…
Novo Nordisk said on Wednesday it had signed a development and license agreement with Canadian biotech Aspect Biosystems worth up to $2.6 billion to develop…
Aspect Biosystems expands its Novo Nordisk partnership (Jan 2026): Aspect gains rights to Novo's stem-cell-derived islet cells and immune-evasion cell…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Novo Nordisk and Aspect Biosystems entered a development and license agreement to develop bioprinted tissue therapeutics for diabetes and obesity. Aspect received $75M in initial payments and is eligible for up to $650M per product across up to four programs (~$2.6B total), plus tiered royalties. UPDATE (Jan 20, 2026): The partners announced a new phase of the alliance focused on curative Type 1 diabetes cell therapy. Aspect acquired rights to Novo Nordisk's stem-cell-derived islet cell and hypoimmune cell-engineering technologies and will now lead development, manufacturing and commercialization, combining them with its bioprinting platform; Novo retains defined rights to expand its role in later-stage development/commercialization, makes an additional (undisclosed) equity investment in Aspect, continues research funding, and is eligible for royalties and milestones on future sales. Programs remain preclinical, advancing toward clinical development. The original 2023 development & license agreement was not terminated.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novo Nordisk A/S / Aspect Biosystems Ltd. (this deal) | 2023 | $2.7B | — |
| Novo Nordisk A/S / Emisphere Technologies | 2020 | $1.4B | 90 |
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. | 2019 | $3.3B | 88 |
| Novo Nordisk A/S / Vivtex Inc. | 2026 | $2.1B | 69 |
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. | 2021 | $3.3B | 68 |
| Novo Nordisk A/S / Forma Therapeutics Holdings Inc. | 2022 | $1.1B | 68 |
| Novo Nordisk A/S / Inversago Pharma | 2023 | $1.1B | 61 |
← Browse all deals · How we score deals
More: 2023 deals · Novo Nordisk A/S deals · Metabolic deals